Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from ImExHS Limited ( (AU:IME) ).
ImExHS Limited reported a strong start to FY26, with first-quarter revenue rising 13% year-on-year to $7.9 million and underlying EBITDA improving to $0.8 million, supported by annual recurring revenue of $34.8 million and stable debt levels. The company is accelerating a strategic pivot to an AI-native, agentic radiology workflow platform, with two of five planned AI agents already live, key new software contracts signed in Latin America, improving margins at its RIMAB radiology services unit, and a strengthened leadership team, although delayed healthcare payments in Colombia are creating near-term cash flow pressures that it is managing through tighter credit controls and pricing discipline.
The most recent analyst rating on (AU:IME) stock is a Buy with a A$0.50 price target. To see the full list of analyst forecasts on ImExHS Limited stock, see the AU:IME Stock Forecast page.
More about ImExHS Limited
ImExHS Limited is an ASX-listed provider of cloud-based medical imaging software and radiology services operating across 18 countries. The company focuses on radiological workflow management, with its Aquila+ platform and related solutions increasingly built around AI-native, agentic technologies aimed at automating end-to-end radiology processes for healthcare providers.
Average Trading Volume: 28,396
Technical Sentiment Signal: Sell
Current Market Cap: A$20.82M
Find detailed analytics on IME stock on TipRanks’ Stock Analysis page.